Clinical Trials Logo

Filter by:
NCT ID: NCT06304987 Not yet recruiting - Clinical trials for Locally Advanced Rectal Cancer

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Start date: April 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, prospective, randomized controlled study to evaluate the effectiveness and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and PCSK9 inhibitor in the treatment of patients with pMMR/MSS locally advanced middle and low rectal cancer.

NCT ID: NCT06303089 Not yet recruiting - Smoking Cessation Clinical Trials

Tobacco Exposure and Influencing Factors of Smoking Cessation Among Chronic Kidney Disease Patients

Start date: April 1, 2024
Phase:
Study type: Observational

The purpose of this study is to describe the tobacco exposure and characteristics of patients with Chronic Kidney Disease (CKD) who quit smoking, to identify patients' tobacco-related knowledge, attitude, and practice (KAP) and explore the influencing factors of smoking cessation.

NCT ID: NCT06303037 Not yet recruiting - Sedation Clinical Trials

Effect of Esketamine on 95% Induction Dose of Remimazolam

EEIDR
Start date: April 2024
Phase: Phase 4
Study type: Interventional

As an invasive operation, gastroscopy will cause children's nervousness, anxiety and uncooperative behavior, and even lead to the risk of bleeding and perforation, which will also affect the accuracy of the examination results.The purpose of this study is to explore the influence of different doses of esketamine on the induced dose ED95 of remazolam during gastroscopic placement in children, and to provide theoretical basis for the combined use of remimazolam besylate and esketamine in gastroscopic anesthesia in children.

NCT ID: NCT06302985 Not yet recruiting - Children Clinical Trials

Atomized Inhalation ICG for Treatment of Congenital Lung Malformations

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

To investigate the safety and effectiveness of preoperative aerosol inhalation ICG solution for thoracoscopic accurate resection of congenital lung malformations in children.

NCT ID: NCT06302803 Not yet recruiting - Obesity Clinical Trials

Modified Intermittent Eating on Weight Loss (INTEREST-3 Trial)

INTEREST-3
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Calorie restriction (CR) is the most important treatment for weighting loss. In recent years, two novel types of intermittent fasting recently have gained more attention: the 5:2 diet and time-restricted eating (TRE). TRE requires individuals to eat in a specified number of hours per day (typically 4 to 10 hours) without energy intake restriction. The 5:2 diet involves 5 feast days and 2 fast days per week; participants eat ad libitum without restriction on feast days while 25% of energy needs (approximately 500-800 kcal per day) are consumed on fast days. However, the effects of dietary strategy of intermittent fasting plus time-restricted eating (modified time-restricted eating: TRE 5 days and fasting 2days per week) on weight loss and cardiometabolic risk factors in obese adults have not been proved. This randomized controlled trial aimed to evaluate the effect of modified time-restricted eating (mTRE) and CR on weight loss and cardiometabolic risk factors in obese adults compared to usual health care over 12 months.

NCT ID: NCT06301438 Not yet recruiting - Clinical trials for Advanced Breast Cancer

Dalpiciclib in HR+/HER2- ABC

Start date: April 25, 2024
Phase:
Study type: Observational

To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.

NCT ID: NCT06301399 Not yet recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

Start date: March 20, 2024
Phase: Phase 2
Study type: Interventional

Evaluation of the efficacy and safety of adding rituximab after failure of target immunotherapy in the Posterior treatment of advanced hepatocellular carcinoma

NCT ID: NCT06301386 Not yet recruiting - Colon Cancer Clinical Trials

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about efficacy of Everolimus in combination with PD-1 in patients with locally advanced and advanced colorectal cancer that cannot be R0 resected. The main question is to explore the survival time, safety and tolerability of the treatment. At the same time, the correlation between biomarkers (including PD-L1 expression, tumor mutation load, lymphocyte subpopulation, cytokines, TCR, intestinal microbes, and others) and the efficacy and drug resistance mechanism will be analyzed, so as to provide reference for the subsequent guidance of the screening of benefit groups.

NCT ID: NCT06301074 Not yet recruiting - Schizophrenia Clinical Trials

The Phase I Study of HS-10509 in Chinese Adult Subjects

Start date: March 2024
Phase: Phase 1
Study type: Interventional

The study is to evaluate the safety, tolerability, and PK characteristics following single administration of HS-10509 in healthy adults, and multiple administrations of HS-10509 in patients with schizophrenia. Participants will have HS-10509 tablets or placebo once in the single ascending dose (SAD) part or once daily for 28 days in the multiple ascending dose (MAD) part.

NCT ID: NCT06300723 Not yet recruiting - Sickle Cell Disease Clinical Trials

Clinical Study of BRL-101 in Severe SCD

Start date: September 25, 2024
Phase: N/A
Study type: Interventional

This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101).